MERS-CoV, Lassa and Nipah - analysing the demand case for new vaccines


22-01-2019

This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases three detailed demand analyses for MERS-CoV, Lassa virus and Nipah virus vaccines.

MERS-CoV, Lassa virus and Nipah virus are pathogens of critical concern due to their pandemic potential. Similar to the Ebola virus, which is currently causing an outbreak in the Democratic Republic of Congo (DRC), MERS-CoV, Lassa virus and Nipah virus can also be transmitted from animal-to-human (zoonotic), between humans and are associated with significant morbidity and mortality.

Of considerable concern is that the animal hosts for these viruses, especially the dromedary camel and fruit bat (Pteropodidae) are present in a large number of countries with limited healthcare infrastructure and substantial vulnerable populations. Unlike the Ebola virus, there are no available vaccines for MERS-CoV, Lassa virus and Nipah virus, although development efforts are underway.

MERS-CoV, Lassa virus and Nipah virus have been designated to be priority pathogens by international healthcare stakeholders such as the World Health Organisation (WHO) and more recently, the Coalition for Epidemic Preparedness Innovations (CEPI) which has funded numerous candidate programs.

To help perpetuate commercial and public interest in the development of vaccines against MERS-CoV, Lassa virus and Nipah virus, VacZine Analytics has conducted detailed demand analyses for potential public and private sector uptake, should development efforts be successful and regulatory licences (or emergency access) granted. Uptake assumptions are aligned with previous funding analysis and ongoing deployment of the Ebola Virus vaccine (rVSV-ZEBOV, Merck & Co) and importantly, are guided by the comparative epidemiological parameters exhibited by these important pathogens. Each demand analysis is composed of a comprehensive Executive Presentation (.pdf) and MS Excel (.xls) value/volume forecast workbook and is available for order.

For more information, please contact info@vaczine-analytics.com or visit www.vaczine-analytics.com

VacZine Analytics, a world-leading supplier of vaccine-related commercial analyses, is a trading division of Assay Advantage Ltd (UK Company No: 5807728, UK VAT: 883584084)

 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)